DANYELZA's estimated total share of the US anti-GD2 market remained steady at approximately 15% as of September 30, 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback